# Nephrosant

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/nephrosant

- Industry: Biotechnology
- Headquarters: Brisbane, US
- Website: www.nephrosant.com
- Total disclosed funding: $16M
- Latest round: Series A (Mar 16, 2021)
- Investors on record: 2

## About

Founded in 2017 by CEO Minnie Sarwal and based in California, US, Nephrosant, Inc., a kidney health spin out of UC San Francisco, operates as a biotechnology company. In March 2021, Nephrosant, Inc. raised USD 16 million in Series A funding led by investor DaVita Venture Group, with participation from DigitalDx Ventures.
 
The company develops and provides QiSant, a kidney transplant rejection test to help the prevention, diagnosis, and treatment of kidney injuries for post-transplant patients. The company also provides a needle-free urine test that helps to determine if a patient's body is rejecting a transplanted kidney. 

The company plans to use the funding raised in Series A to support further research and development.

## Funding rounds

- Series A, Mar 16, 2021, $16M — DigitalDx Ventures, DaVita Venture Group
- Series A, Jan 1, 2020 — DigitalDx Ventures, DaVita Venture Group

## Investors

- DigitalDx Ventures (https://capitalatlas.ai/funds/digitaldx-ventures) — Series A
- DaVita Venture Group (https://capitalatlas.ai/funds/davita-venture-group) — Series A